{
    "organizations": [],
    "uuid": "c69176a9c468fd7e7219a13935e0b30df470adfa",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-case-western-reserve-sangamo-thera/brief-case-western-reserve-sangamo-therapeutics-get-11-mln-nih-grant-idUSFWN1PX11P",
    "ord_in_thread": 0,
    "title": "BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Sangamo Therapeutics Inc:\n* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV\n* NO SB-728-T PRODUCT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED IN SANGAMOâ€˜S SB-728-T CLINICAL TRIALS\n* CO WILL BE CONTRIBUTING MATERIALS, EQUIPMENT, AND MANUFACTURING EXPERTISE FOR STUDY, WHICH IS EXPECTED TO BEGIN IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-07T20:45:00.000+02:00",
    "crawled": "2018-02-09T05:56:39.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sangamo",
        "therapeutic",
        "inc",
        "case",
        "western",
        "reserve",
        "sangamo",
        "therapeutic",
        "announce",
        "million",
        "nih",
        "grant",
        "study",
        "cell",
        "viral",
        "eradication",
        "hiv",
        "serious",
        "adverse",
        "event",
        "reported",
        "sangamo",
        "clinical",
        "trial",
        "co",
        "contributing",
        "material",
        "equipment",
        "manufacturing",
        "expertise",
        "study",
        "expected",
        "begin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}